OptiBiotix signs US pharmaceutical deal for its cholesterol reducing Lactobacillus plantarum strain
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an agreement with a US company (“The Company”) for the use […]
